Journey Medical Patent-Cliff Exposure & CMS Drug Spending Portfolio

Journey Medical (US): 6 reconciled FDA prescription therapies (14.7% 2025 to 2030 cliff risk), $2.9M 2024 CMS Part D & Medicaid spend, and $1,298 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure14.7%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$2.9M
2024 Medicare Part D Spend$2.9M
2024 Medicaid Spend$0
California HCAI SB 17 FilingsSpecialty launch notice ($1,298 intro WAC)